Kolbert covers the Healthcare sector, focusing on stocks such as BioCardia, Can-Fite BioPharma, and Daré Bioscience. According to TipRanks, Kolbert has an average return of -5.1% and a 33.42% success rate on recommended stocks.
Currently, the analyst consensus on Cytosorbents is a Moderate Buy with an average price target of $10.75, which is a 636.30% upside from current levels. In a report released on November 4, H.C. Wainwright also maintained a Buy rating on the stock with a $5.50 price target.
Based on Cytosorbents’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $6.46 million and a GAAP net loss of $12.2 million. In comparison, last year the company earned a revenue of $8.9 million and had a GAAP net loss of $6.41 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CytoSorbents Corp. engages in the research and development of blood purification technology for the reduction of deadly uncontrolled inflammation in hospitalized patients. Its product include CytoSorb, ContrastSorb, HemoDefend, VetResQ, and DrugSorb. The company was founded by Joseph Rubin on April 25, 2002 and is headquartered in Monmouth Junction, NJ.
Read More on CTSO: